Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B
October 31, 2019 at 06:30 AM EDT
One of the leading Cambridge biotechs hoping to treat diseases by silencing the genetic causes could get as much as $1.67 billion to develop a treatment for hepatitis B.
